YaFarm Technologies Taps Esteemed Industry Professionals for Leadership Roles at the ISCI
11 Février 2013 - 1:47PM
Marketwired
YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the
Company) announced today the appointment of top level management
for the Integrative Stem Cell Institute (ISCI), a premier provider
of point-of-care, stem cell-based therapies. YaFarm announced that
David Audley has been appointed CEO of the ISCI, while Juan A.
Castillo has been elected Chairman of the Board of Directors.
YaFarm expects to announce members of its Board of Directors and
Advisory Board in the near future.
Dr. Castillo, originally from Spain, has practiced medicine in
Miami as an OB-GYN physician and laser surgeon for over three
decades. Recognizing that many of the important needs and
debilitating conditions of naturally aging women are not addressed
in the traditional practice of medicine, he developed the
Integrative Stem Cell Institute to provide cellular medical
services to enhance, improve, and restore those needs and chronic
conditions associated with aging. Dr. Castillo chose to place his
institute in the Hospital Galenia because of its reputation for
tremendous patient care and its staff of internationally recognized
medical experts. Dr. Castillo is a pioneer in regenerative medicine
and has successfully treated over 250 patients using adult stem
cells. Dr. Castillo has been elected to the chairmanship of the
board of directors for the ISCI where he will provide strategic
vision and oversight.
David Audley has been appointed CEO of the ISCI. As CEO, Mr.
Audley will oversee the day-to-day management of the ISCI, as well
as its facilities in Cancun. Mr. Audley comes to the ISCI after
successfully managing the International Cellular Medicine Society
(ICMS) for nearly 4 years. As the founding executive director and
CEO of the ICMS, Mr. Audley grew the organization from 7 physicians
to over 3500 members from 35 countries. Under his leadership, the
ICMS built the first registry of patient outcomes from stem cell
treatments, published comprehensive guidelines and standards for
the practice of cell-based medicine and developed a global program
to evaluate laboratories and facilities involved in regenerative
medicine. Mr. Audley also provided the leadership that resulted in
the alliance between the ICMS and the AABB to combine the standards
of the ICMS with the accreditation program and expertise of the
AABB. Mr. Audley is a noted expert in field of regenerative
medicine and has spoken extensively on global trends and
perspectives.
Brian Hermenze, CEO of YaFarm Technologies, said, "Dr. Castillo
and Mr. Audley will provide the executive leadership to take the
post-merger ISCI to the next level. As a result of their
affiliation, we were able to announce last week that we concluded a
definitive agreement with the Hospital Galenia to provide stem cell
treatments at the medical center." Mr. Hermenze continued, "The
combination of Dr. Castillo's medical expertise and Mr. Audley's
experience in the field is as good as it gets. Together, they will
redefine the standard for care in regenerative medicine. I am
excited about the potential for the ISCI under their
leadership."
About Integrative Stem Cell Institute
(ISCI) The Integrative Stem Cell Institute (ISCI) is a premier
provider of point-of-care, stem cell-based therapies for patients
from around the world. With a state of the art laboratory housed
within the Hospital Galenia in Cancun, Mexico, the ISCI combines
the most advanced scientific application of stem cells with second
to none medical care within the structure of adaptive clinical
trials to effective track long term outcomes and assure patient
safety. More information on the Integrative Stem Cell Institute is
available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking
statements and information, as defined within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, and is subject to the Safe Harbor
created by those sections. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. This material contains statements about
expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward looking
statements are subject include, but are not limited to, the effect
of government regulation, competition, adequate financing, and
other material risks. Such forward-looking statements by definition
involve risks, uncertainties and other factors, which may cause the
actual results, performance, or achievements to be materially
different from the statements made herein.
Contact: The Integrative Stem Cell Institute Contact: Miranda
Abrahams Miranda@iscelli.com Investor Contact Atlanta Capital
Partners, LLC David Kugelman (866) 692-6847 info@atlcp.com
Profile Solutions (CE) (USOTC:PSIQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Profile Solutions (CE) (USOTC:PSIQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024